

# Xlife Sciences AG Valuation Report 2022

Valuation as of December 31<sup>st</sup> 2022

Zurich / Pfaffikon SZ, April 27<sup>th</sup> 2023

# Xlife Sciences AG Valuation Report 2022

## Disclaimer

This Valuation Report has been prepared by CYLAD Experts AG ("CYLAD") for informational and background purposes and represents the opinion of CYLAD and not the opinion of Xlife Sciences Ltd (the "Company"), any of its subsidiaries or affiliates.

For the purpose of preparing this Valuation Report, CYLAD relied on the information provided by the Company. In particular, CYLAD did not perform any independent research (due diligence) on the companies listed in this Valuation Report.

For the purpose of the valuations presented in this Valuation Report, CYLAD has assumed that the respective companies will be able to meet the necessary financing requirements. If this assumption does not apply, the results may differ significantly from those presented in this Valuation Report.

This Valuation Report is not, and should not be construed as, a prospectus or offering document. It has not been reviewed or approved by any governmental authority. The information in this Valuation Report does not constitute, and should not be construed as, an offer to sell or subscribe for, or the solicitation or invitation of an offer to subscribe for or purchase, any shares or other investments in the Company, any of its subsidiaries, its affiliates or any other company. In particular, this Valuation Report may not serve as a basis for an investment decision or as a support in connection with an investment decision or the conclusion of an agreement.

Neither the Company nor any of its subsidiaries or affiliates, directors, officers, employees or advisors (the "Representatives") or CYLAD makes any representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or correctness of the information or opinions contained in this Valuation Report or any other statement relating to the Company, any of its subsidiaries or affiliates for any purpose, including, without limitation, investment considerations. No liability of any kind for any reason whatsoever for any loss, damage or expense in connection with the use of any information, opinion, omission or inaccuracy contained in this Valuation Report will be accepted by the Company, any of its subsidiaries or affiliates, their representatives or CYLAD.

This Valuation Report contains forward-looking statements, including, but not limited to, projections about financial developments, market activities, future performance of products or proposed transactions that involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known and unknown risks and various other factors, which could cause actual results, performance or events to differ materially from the statements made herein. If any of these risks or uncertainties materialize, or if the explicit or implicit assumptions underlying any forward-looking statements prove incorrect, actual results may be materially different from those expressed or implied by the statements in this Valuation Report. Neither the Company nor any of its subsidiaries, affiliates, representatives or CYLAD intends or assumes any obligation to update these forward-looking statements.

This Valuation Report does not constitute a prospectus or similar communication within the meaning of the Swiss Financial Services Act.

This Valuation Report will not be registered under the Securities Act of 1933 of the United States of America and any securities of the Company may not be offered or sold in the United States of America absent registration or an exemption from the registration requirements of the Act. This Valuation Report is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended) and is not a prospectus for the purposes of Regulation (EU) 2017/1129 under the European Union (Withdrawal) Act 2018.

# Xlife Sciences AG Valuation Report 2022

## Table of content

### Executive Summary

Page 4

### Portfolio analysis

Page 7

### Valuation of project companies in detail

Page 15

### Appendix

Page 34

# Xlife Sciences AG Valuation Report 2022

## Executive Summary (1/2)

Xlife Sciences AG is a publicly listed management company focussing on the life science industry and reporting according to IFRS regulations. Since February 11th 2022, Xlife Sciences is listed at the SIX Swiss Exchange. Xlife Sciences focusses on the "value development and commercialization of promising research projects of universities and other research institutions in the field of life sciences with the goal of providing solutions for a high unmet medical need and a better quality of life."

The company acts as „an accelerator & incubator in the areas of technology platforms, biotechnology/therapies, medical technology & artificial intelligence (AI) in the life science sector with a focus on the European DACH market.“ The company has numerous partnerships, especially with German universities (including Heidelberg, Jena, Tübingen, Münster) and other partners.

The business model consists of the early recognition of promising research projects, commercial development of those projects and realizing profits either in the short/medium term through industry-tradesales or IPOs or in the medium/long term through license- and / or royalty deals. The company employs about 20 staff members. The headquarter is located in Zurich, Switzerland.

As of end of 2022, the Xlife Sciences portfolio includes 26 project companies (1 license deal). Total stock market value corresponds to approx. MCHF 180 with approx. 46% free float.

In 2022, Cylad was tasked by Xlife Sciences with the valuation of all project companies as of reporting date December 31<sup>st</sup> 2022. The engagement did aim at a portfolio-wide, harmonized and standardized professional valuation of all projects of Xlife Sciences.

The valuation was conducted from July to December 2022. The Xlife Sciences and the respective project companies were not involved in the valuation, yet support was always offered by providing information. The assessment bases on various financial information provided by Xlife Sciences (e.g. business plans) and additional information obtained through interviews and on site visits with Xlife Sciences and the project companies.

Management data was updated and reviewed in joint work (no due diligence) and subsequently transferred by Cylad into an overall assessment. Cylad did concentrate on the correct and consistent implementation of the assessment according to professional standards. Results are based on documents provided by Xlife Sciences, the various project companies and the available empirical data.

Valuations have been considered in the end of year financial statements 2022 of Xlife Sciences (reporting at fair value, at equity or fully consolidated).

# Xlife Sciences Valuation Report 2022

## Executive Summary (2/2)

### Comments

- Cylad has been mandated by Xlife Sciences AG to evaluate its portfolio in project company shares as of December 31st 2022
- The works of Cylad have been based on documents & information provided by Xlife Sciences AG and management members of the various project companies (valuation does not include any due diligence of information received)
- In the valuation process, Cylad did apply a risk-adjusted net present value (rNPV) approach as well as the standard net present value (NPV) approach
- As of December 31st 2022, the portfolio of Xlife Sciences AG is valued at MCHF 576.0 to 704.5 (indicative value range)
- Not included are project companies not yet ready for valuation

### Value of Xlife Sciences project company portfolio as of 31.12.2022 (in CHF)

Technology Platforms	Share	Valuation		
Inventum Genetics GmbH	100.00%	57'800'000	to	70'700'000
palleos healthcare GmbH	50.00%	4'800'000	to	5'800'000
Veraxa Biotech AG	18.23%	105'300'000	to	128'700'000
Biotech & Therapies				
alytas therapeutics GmbH	51.04%	152'900'000	to	186'900'000
Baliopharm AG	0.00%	9'400'000	to	11'500'000
inflamed pharma GmbH	75.00%	83'500'000	to	102'100'000
Ix Therapeutics GmbH	50.00%	2'500'000	to	3'100'000
Lysatpharma GmbH	25.20%	30'500'000	to	37'300'000
panmabs GmbH	46.21%	not been evaluated yet		
QUADIRA BIOSCIENCES AG	50.00%	16'800'000	to	20'600'000
Synimmune Biotech AG	37.36%	10'700'000	to	13'100'000
xarma life sciences GmbH	46.21%	3'600'000	to	4'400'000
XRNA Biotech GmbH <sup>1</sup>	100.00%	not been evaluated yet		
xprot GmbH	100.00%	not been evaluated yet		
Medical Technology & Diagnostics				
Axenoll Life Sciences AG	13.97%	17'700'000	to	21'700'000
clyxop devices GmbH	70.00%	900'000	to	1'100'000
Laxxon Medical Corp.	4.66%	8'200'000	to	10'000'000
novaxomx GmbH	40.00%	not been evaluated yet		
Novum Technologie GmbH	66.60%	not been evaluated yet		
saniva diagnostics GmbH	19.00%	7'900'000	to	9'700'000
VITRUVIA MEDICAL AG	5.47%	100'000	to	200'000
x-kidney diagnostics GmbH	100.00%	3'100'000	to	3'800'000
x-nuclear diagnostics GmbH	100.00%	11'600'000	to	14'200'000
Xsight Optics GmbH	80.00%	16'700'000	to	20'400'000
Artificial Intelligence				
FUSE-AI GmbH	35.00%	32'000'000	to	39'200'000
x-diagnostics GmbH	100.00%	not been evaluated yet		
		576'000'000	to	704'500'000

# Xlife Sciences AG Valuation Report 2022

## Table of content

### Executive Summary

Page 4

### Portfolio analysis

Page 7

### Valuation of projects in detail

Page 15

### Appendix

Page 34

# Xlife Sciences AG Valuation Report 2022


## Overview on valuation results

Technology Platforms	Share		Valuation	
Inventum Genetics GmbH	100.00%	57'800'000	to	70'700'000
palleos healthcare GmbH	50.00%	4'800'000	to	5'800'000
Veraxa Biotech AG	18.23%	105'300'000	to	128'700'000
Biotech & Therapies				
alytas therapeutics GmbH	51.04%	152'900'000	to	186'900'000
Baliopharm AG	0.00%	9'400'000	to	11'500'000
inflamed pharma GmbH	75.00%	83'500'000	to	102'100'000
Ix Therapeutics GmbH	50.00%	2'500'000	to	3'100'000
Lysatpharma GmbH	25.20%	30'500'000	to	37'300'000
panmabs GmbH	46.21%		not been evaluated yet	
QUADIRA BIOSCIENCES AG	50.00%	16'800'000	to	20'600'000
Synimmune Biotech AG	37.36%	10'700'000	to	13'100'000
xarma life sciences GmbH	46.21%	3'600'000	to	4'400'000
XRNA Biotech GmbH <sup>1</sup>	100.00%		not been evaluated yet	
xprot GmbH	100.00%		not been evaluated yet	
Medical Technology & Diagnostics				
Axenoll Life Sciences AG	13.97%	17'700'000	to	21'700'000
clyxop devices GmbH	70.00%	900'000	to	1'100'000
Laxxon Medical Corp.	4.66%	8'200'000	to	10'000'000
novaxomx GmbH	40.00%		not been evaluated yet	
Novum Technologie GmbH	66.60%		not been evaluated yet	
saniva diagnostics GmbH	19.00%	7'900'000	to	9'700'000
VITRUVIA MEDICAL AG	5.47%	100'000	to	200'000
x-kidney diagnostics GmbH	100.00%	3'100'000	to	3'800'000
x-nuclear diagnostics GmbH	100.00%	11'600'000	to	14'200'000
Xsight Optics GmbH	80.00%	16'700'000	to	20'400'000
Artificial Intelligence				
FUSE-AI GmbH	35.00%	32'000'000	to	39'200'000
x-diagnostics GmbH	100.00%		not been evaluated yet	
		576'000'000	to	704'500'000


# Xlife Sciences AG Valuation Report 2022

## Portfoliomix in detail


Portfoliomix by project value




Portfoliomix by segment




Portfoliomix by development phase



Portfoliomix by market risk (WACC)



Portfoliomix by development risk (success rates)






# alytas therapeutics GmbH remains biggest position – Veraxa Biotech on the rise

## Portfoliomix by project value


Comments
<ul style="list-style-type: none"><li>As of December 31st 2022, Xlife Sciences AG holds shares in 26 project companies (incl. 1 license deal)</li><li>Largest single position: 51.04% share in alytas therapeutics GmbH equaling roughly 27% of the total portfolio value</li><li>Top 6 out of 26 positions equaling 80% of total portfolio value<ul style="list-style-type: none"><li>alytas therapeutics GmbH 27%</li><li>Veraxa Biotech AG 18%</li><li>inflamed pharma GmbH 14%</li><li>Inventum Genetics GmbH 10%</li><li>FUSE-AI GmbH 6%</li><li>Lysatpharma GmbH 5%</li></ul></li><li>Remaining 20 project companies equal 20% of total portfolio value</li></ul>



# Strong focus on Biotech & therapies segment flanked mainly by technology platforms

## Portfoliomix by segments


Comments
<ul style="list-style-type: none"><li>▪ Xlife Sciences AG holds shares in four different market segments<ul style="list-style-type: none"><li>▸ Technology platforms</li><li>▸ Biotech &amp; therapies</li><li>▸ Medtech &amp; diagnostics</li><li>▸ Artificial Intelligence (AI)</li></ul></li><li>▪ Xlife Sciences AG focussing on Biotech &amp; therapies: 54% of portfolio value</li><li>▪ Top 2 segments equal &gt;80% of total portfolio value<ul style="list-style-type: none"><li>▸ Biotech &amp; therapies: 54%</li><li>▸ Technology platforms: 29%</li></ul></li><li>▪ Remaining positions in Medtech &amp; diagnostics (11%) and Artificial Intelligence (6%) as minor shares in the portfoliomix</li></ul>



# Strong emphasis on early stage projects – though 23% already operational in market

## Portfoliomix by development phase


Comments
<ul style="list-style-type: none"><li>▪ The incubator and accelerator business model of Xlife Sciences AG emphasis projects in the very early development stages</li><li>▪ 53% of total portfolio value in proof-of-concept phase</li><li>▪ 77% of total portfolio value range from proof-of-concept till approval phase<ul style="list-style-type: none"><li>▶ 53% in proof-of-concept phase</li><li>▶ 17% in 1st-3rd clinical phase</li><li>▶ 7% in approval phase</li></ul></li><li>▪ 23% of total project value is already operational in the respective markets reflecting only parts of Xlife Sciences current potential for exit-strategies</li></ul>



# Market risks well diversified across the board

## Portfoliomix by market risk (WACC)


Comments
<ul style="list-style-type: none"><li>▪ In the risk adjusted net present value model (rNPV), market risks are reflected in the applied weighted average costs of capital (WACC)</li><li>▪ The higher the market risk, the higher the applied WACC<ul style="list-style-type: none"><li>▶ 22.86% WACC: very high market risk</li><li>▶ 20.32% WACC: high market risk</li><li>▶ 15.24% and 17.78% WACC: low and average market risk</li></ul></li><li>▪ 97% of total portfolio value range from comparatively low to high market risks<ul style="list-style-type: none"><li>▶ 39% with high market risks</li><li>▶ 27% with average market risks</li><li>▶ 31% with low market risks</li></ul></li><li>▪ Only 3% of total portfolio value with a maximum of high market risks</li></ul>



# High development risks as part of Xlife Sciences AG business model

## Portfoliomix by development risk (success rates)

Comments
<ul style="list-style-type: none"><li>▪ In the risk adjusted net present value model (rNPV), market risks and development risks are accounted for separately</li><li>▪ Development risks measured in the overall cumulated success rate are highly sensitive specifically with regard to project values, milestone achievements in the development process have a major leverage</li><li>▪ Xlife Sciences AG with its incubator and accelerator business model has a strong focus on (very) early stage projects with high leverage potentials depending on further development success</li><li>▪ Xlife Sciences business model reflected in development risks:<ul style="list-style-type: none"><li>▶ 48% of total value in highest risk rate (cum. success rate 1-10%)</li><li>▶ 25% of total value as high risk projects (11-20%)</li><li>▶ 23% with average development risks (21-40%) and 4% with low development risks (41-100%)</li></ul></li></ul>



# Xlife Sciences AG Valuation Report 2022

## Table of content

### Executive Summary

Page 4

### Portfolio analysis

Page 7

### Valuation of project companies in detail

Page 15

### Appendix

Page 34

# Valuation of project companies in detail

## Preliminaries

- As of December 31st 2022, the portfolio of Xlife Sciences AG includes 26 project companies (including 1 license deal).
- Not addressed by Cylad (but other sources):
  - ▶ Baliopharm AG: Licence Deal, values provided according to Baliopharm AG Management resp. Xlife Sciences AG
  - ▶ Laxxon Medical Corp.: Has been valued separately according to ongoing pre-exit-phase by 3<sup>rd</sup> parties, management, Xlife Sciences AG
  - ▶ VITRUVIA MEDICAL AG: Company is listed at stock exchange, valuation based on stock exchange price according to data Xlife Sciences AG
- Not evaluated yet (very early stage project companies):
  - ▶ novaxomx GmbH
  - ▶ Novum Technologie GmbH
  - ▶ panmabs GmbH
  - ▶ xprot GmbH
  - ▶ XRNA Biotech GmbH<sup>1</sup>
  - ▶ x-diagnostics GmbH

Inventum Genetics GmbH


Fact Sheet



<div>Activity &amp; Business model</div> <ul style="list-style-type: none"><li>▪ Identification &amp; development of innovative therapies &amp; biomarkers for common diseases based on human data (GWAS, eQTL)</li><li>▪ License Model</li></ul>		<div>Development phase</div> <div><div>PoC</div></div>		<div>Portfolio segment</div> <div><div>Platform</div><div>BioTech</div><div>MedTech</div><div>AI</div></div> <div>Platform</div>																																					
<div>Modeling</div> <ul style="list-style-type: none"><li>▪ Category: Fully consolidated</li><li>▪ Method: rNPV</li><li>▪ Terminal Value: Phase Out 5 years</li><li>▪ Cum Success Rate: 16%</li><li>▪ WACC / Rational: 20.32% / Startup with market risks</li></ul>		<div>Valuation</div> <table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>58'383'838</td><td colspan="2">71'414'141</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>58'383'838</td><td colspan="2">71'414'141</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>100.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>58'383'838</td><td colspan="2">71'414'141</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>57'800'000</td><td colspan="2">70'700'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	58'383'838	71'414'141		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	58'383'838	71'414'141		Equity share Xlife Sciences		100.00%		Equity value Xlife Sciences share (EUR)	58'383'838	71'414'141		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	57'800'000	70'700'000	
	from	to																																							
Company valuation (100%) (EUR)	58'383'838	71'414'141																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	58'383'838	71'414'141																																							
Equity share Xlife Sciences		100.00%																																							
Equity value Xlife Sciences share (EUR)	58'383'838	71'414'141																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	57'800'000	70'700'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2019	100.00%	License	Mainz, Germany	www.inventumgenetics.com																																					


\* Values rounded





Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Full service clinical research organization (CRO), that offers end-to-end services ranging from clinical development to performing comprehensive medical studies</li><li>Established company operating in German market, &gt;5 year track record</li></ul>				<div>PlatformBioTechMedTechAI</div> <div>Platform</div>																																					
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Equity</li><li>Method: NPV</li><li>Terminal Value: Perpetual Growth Rate 5%</li><li>Cum Success Rate: ---</li><li>WACC / Rational: 15.24% / established company with track record</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>9'696'970</td><td colspan="2">11'717'172</td></tr><tr><td>Net financial liabilities</td><td>0</td><td colspan="2">0</td></tr><tr><td>Non-operating assets</td><td>0</td><td colspan="2">0</td></tr><tr><td>Equity value (EUR)</td><td>9'696'970</td><td colspan="2">11'717'172</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>50.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>4'848'485</td><td colspan="2">5'858'586</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>4'800'000</td><td colspan="2">5'800'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	9'696'970	11'717'172		Net financial liabilities	0	0		Non-operating assets	0	0		Equity value (EUR)	9'696'970	11'717'172		Equity share Xlife Sciences		50.00%		Equity value Xlife Sciences share (EUR)	4'848'485	5'858'586		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	4'800'000	5'800'000	
	from	to																																							
Company valuation (100%) (EUR)	9'696'970	11'717'172																																							
Net financial liabilities	0	0																																							
Non-operating assets	0	0																																							
Equity value (EUR)	9'696'970	11'717'172																																							
Equity share Xlife Sciences		50.00%																																							
Equity value Xlife Sciences share (EUR)	4'848'485	5'858'586																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	4'800'000	5'800'000																																							
Founded	Share	Exit scenario	Location		Website																																				
2013	50.00%	Trade sale	Wiesbaden, Germany		www.palleos.com																																				

\* Values rounded




Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>▪ Microfluid screening for detection of functional antibodies, development of antibody drug conjugates (ADCs) through innovative chem-based approach</li><li>▪ Manufacturing of antibodies as well as licence model in case of customer specific antibodies</li></ul>				<div>PlatformBioTechMedTechAI</div> <div>Platform</div>																																					
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>▪ Category: Fair Value</li><li>▪ Method: rNPV</li><li>▪ Terminal Value: Phase Out 5 years</li><li>▪ Cum Success Rate: License Model 6%</li><li>▪ WACC / Rational: 15.24% / Established company</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>583'453'847</td><td colspan="2">713'110'258</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>583'453'847</td><td colspan="2">713'110'258</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>18.23%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>106'363'636</td><td colspan="2">130'000'000</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>105'300'000</td><td colspan="2">128'700'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	583'453'847	713'110'258		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	583'453'847	713'110'258		Equity share Xlife Sciences		18.23%		Equity value Xlife Sciences share (EUR)	106'363'636	130'000'000		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	105'300'000	128'700'000	
	from	to																																							
Company valuation (100%) (EUR)	583'453'847	713'110'258																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	583'453'847	713'110'258																																							
Equity share Xlife Sciences		18.23%																																							
Equity value Xlife Sciences share (EUR)	106'363'636	130'000'000																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	105'300'000	128'700'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2020	18.23%	Trade sale / IPO	Zurich, Switzerland	www.veraxa.com																																					



\* Values rounded

<div>Activity &amp; Business model</div> <div><ul style="list-style-type: none"><li>Development of new immunology based therapy concepts for treating obesity, overweight &amp; senescence</li><li>Spin-off University Hospital Jena</li><li>Business Modell: Obesity = Manufacturer / Senescence = License Model</li></ul></div>		<div>Development phase</div> <div></div>		<div>Portfolio segment</div> <div><table><tr><td>Platform</td><td>BioTech</td><td>MedTech</td><td>AI</td></tr></table><div></div></div>		Platform	BioTech	MedTech	AI																																									
Platform	BioTech	MedTech	AI																																															
<div>Modeling</div> <div><ul style="list-style-type: none"><li>Category: Fully consolidated</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 5.4%</li><li>WACC / Rational: 20.32% / Conservative approach</li></ul></div>		<div>Valuation</div> <table><tr><th></th><th colspan="2">from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td colspan="2">302'594'915</td><td colspan="2">369'882'208</td></tr><tr><td>Net financial liabilities</td><td colspan="2">0</td><td colspan="2">0</td></tr><tr><td>Non-operating assets</td><td colspan="2">0</td><td colspan="2">0</td></tr><tr><td>Equity value (EUR)</td><td colspan="2">302'594'915</td><td colspan="2">369'882'208</td></tr><tr><td>Equity share Xlife Sciences</td><td colspan="2"></td><td>51.04%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td colspan="2">154'444'444</td><td colspan="2">188'787'879</td></tr><tr><td>Exchange rate EUR/CHF</td><td colspan="2"></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td colspan="2">152'900'000</td><td colspan="2">186'900'000</td></tr></table>					from		to		Company valuation (100%) (EUR)	302'594'915		369'882'208		Net financial liabilities	0		0		Non-operating assets	0		0		Equity value (EUR)	302'594'915		369'882'208		Equity share Xlife Sciences			51.04%		Equity value Xlife Sciences share (EUR)	154'444'444		188'787'879		Exchange rate EUR/CHF			0.99		Equity value Xlife Sciences share (CHF)	152'900'000		186'900'000	
	from		to																																															
Company valuation (100%) (EUR)	302'594'915		369'882'208																																															
Net financial liabilities	0		0																																															
Non-operating assets	0		0																																															
Equity value (EUR)	302'594'915		369'882'208																																															
Equity share Xlife Sciences			51.04%																																															
Equity value Xlife Sciences share (EUR)	154'444'444		188'787'879																																															
Exchange rate EUR/CHF			0.99																																															
Equity value Xlife Sciences share (CHF)	152'900'000		186'900'000																																															
<div>Founded</div> <div>2018</div>	<div>Share</div> <div>51.04%</div>	<div>Exit scenario</div> <div>License / Sale</div>	<div>Location</div> <div>Jena, Germany</div>	<div>Website</div> <div>www.alytastherapeutics.com</div>																																														



\* Values rounded

Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>GMP certified development and manufacturing of active ingredients with improved features (e.g. membrane permeability, water-solubility), current focus on ProCluster for treatment of inflammatory pain</li><li>Manufacturer- &amp; License business model</li></ul>		 1. clinical phase		<table><tr><td>Platform</td><td>BioTech</td><td>MedTech</td><td>AI</td></tr><tr><td colspan="4">▲ BioTech</td></tr></table>		Platform	BioTech	MedTech	AI	▲ BioTech																															
Platform	BioTech	MedTech	AI																																						
▲ BioTech																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Fully consolidated</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 21%</li><li>WACC / Rational: 17.78% / Established company with approval risks</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>112'323'232</td><td colspan="2">137'373'737</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>112'323'232</td><td colspan="2">137'373'737</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>75.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>84'242'424</td><td colspan="2">103'030'303</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>83'400'000</td><td colspan="2">102'000'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	112'323'232	137'373'737		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	112'323'232	137'373'737		Equity share Xlife Sciences		75.00%		Equity value Xlife Sciences share (EUR)	84'242'424	103'030'303		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	83'400'000	102'000'000	
	from	to																																							
Company valuation (100%) (EUR)	112'323'232	137'373'737																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	112'323'232	137'373'737																																							
Equity share Xlife Sciences		75.00%																																							
Equity value Xlife Sciences share (EUR)	84'242'424	103'030'303																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	83'400'000	102'000'000																																							
Founded	Share	Exit scenario	Location		Website																																				
2019	75.00%	License / Sale	Jena, Germany		www.inflamedpharma.com																																				


\* Values rounded

Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Development of new functional antibodies for cancer-treatments (currently three), AI-based target-identification in omics-patient data</li><li>Co-Founder Indivumed GmbH, Joint Venture</li><li>License model</li></ul>																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Equity</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 6%</li><li>WACC / Rational: 17.78% / Start-up company with promising first results</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>5'050'505</td><td colspan="2">6'262'626</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>5'050'505</td><td colspan="2">6'262'626</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>50.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>2'525'253</td><td colspan="2">3'131'313</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>2'500'000</td><td colspan="2">3'100'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	5'050'505	6'262'626		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	5'050'505	6'262'626		Equity share Xlife Sciences		50.00%		Equity value Xlife Sciences share (EUR)	2'525'253	3'131'313		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	2'500'000	3'100'000	
	from	to																																							
Company valuation (100%) (EUR)	5'050'505	6'262'626																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	5'050'505	6'262'626																																							
Equity share Xlife Sciences		50.00%																																							
Equity value Xlife Sciences share (EUR)	2'525'253	3'131'313																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	2'500'000	3'100'000																																							
Founded	Share	Exit scenario	Location		Website																																				
2021	50.00%	License	Hamburg, Germany		www.ix-therapeutics.com																																				

\* Values rounded

Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Development of new nanovesicle-based therapeutic approaches for the treatment of acute, chronic, local as well as systemic inflammatory diseases.</li><li>Spin-off University Hospital Jena</li><li>License model</li></ul>																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Equity</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 17%</li><li>WACC / Rational: 17.78% / Established company, promising preliminary development results</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>122'254'289</td><td colspan="2">149'510'983</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>122'254'289</td><td colspan="2">149'510'983</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>25.20%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>30'808'081</td><td colspan="2">37'676'768</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>30'500'000</td><td colspan="2">37'300'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	122'254'289	149'510'983		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	122'254'289	149'510'983		Equity share Xlife Sciences		25.20%		Equity value Xlife Sciences share (EUR)	30'808'081	37'676'768		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	30'500'000	37'300'000	
	from	to																																							
Company valuation (100%) (EUR)	122'254'289	149'510'983																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	122'254'289	149'510'983																																							
Equity share Xlife Sciences		25.20%																																							
Equity value Xlife Sciences share (EUR)	30'808'081	37'676'768																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	30'500'000	37'300'000																																							
Founded	Share	Exit scenario	Location		Website																																				
2018	25.20%	License / Sale	Eisenberg, Germany		www.lysatpharma.com																																				

\* Values rounded


<div>Activity &amp; Business model</div> <div><ul style="list-style-type: none"><li>Design, screening &amp; enhancement of highly effective therapeutic antibody-drug-conjugates (ADCs)</li><li>Cooperation with Veraxa Biotech / Joint Venture with Anfass Technologies</li><li>License model</li></ul></div>		<div>Development phase</div> <div> PoC</div>		<div>Portfolio segment</div> <div><div>Platform</div><div>BioTech</div><div>MedTech</div><div>AI</div><div>BioTech</div></div>																																					
<div>Modeling</div> <div><ul style="list-style-type: none"><li>Category: Equity</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 17%</li><li>WACC / Rational: 17.78% / Start-up with successful studies &amp; established partners</li></ul></div>		<div>Valuation</div> <table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>34'141'414</td><td colspan="2">41'616'162</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>34'141'414</td><td colspan="2">41'616'162</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>50.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>17'070'707</td><td colspan="2">20'808'081</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>16'900'000</td><td colspan="2">20'600'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	34'141'414	41'616'162		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	34'141'414	41'616'162		Equity share Xlife Sciences		50.00%		Equity value Xlife Sciences share (EUR)	17'070'707	20'808'081		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	16'900'000	20'600'000	
	from	to																																							
Company valuation (100%) (EUR)	34'141'414	41'616'162																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	34'141'414	41'616'162																																							
Equity share Xlife Sciences		50.00%																																							
Equity value Xlife Sciences share (EUR)	17'070'707	20'808'081																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	16'900'000	20'600'000																																							
<div>Founded</div> <div>2021</div>	<div>Share</div> <div>50.00%</div>	<div>Exit scenario</div> <div>License</div>	<div>Location</div> <div>Solothurn, Switzerland</div>	<div>Website</div> <div>www.quadirabiosciences.com</div>																																					

\* Values rounded

# Synimmune Biotech AG

## Fact Sheet




<div>Activity &amp; Business model</div> <div><ul style="list-style-type: none"><li>Share of Xlife Sciences AG in Synimmune Biotech AG with Synimmune GmbH as a subsidiary, spin-off University of Tübingen, development of mono- &amp; bi-specific antibodies for cancer treatment FLYSYN (1<sup>st</sup> clinical phase) for the treatment of AML, TACSYN (pre-clinical) for the treatment of ALL, manufacturer</li></ul></div>		<div>Development phase</div> <div><div>1st phase (FLYSYN)</div></div>		<div>Portfolio segment</div> <div><div>Platform</div><div>BioTech</div><div>MedTech</div><div>AI</div><div>BioTech</div></div>																																														
<div>Modeling</div> <div><ul style="list-style-type: none"><li>Category: Equity</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 16%</li><li>WACC / Rational: 15.24% / FLYSYN been applied successfully &amp; has passed 1<sup>st</sup> clinical phase, established company</li></ul><p>Please note: Xlife Sciences AG holds a 37.36% share in Synimmune Biotech AG resp. indirectly a 30.37% share in Synimmune Biotech GmbH (subsidiary company)</p></div>		<div>Valuation</div> <table><tr><th></th><th colspan="2">from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td colspan="2">28'929'552</td><td colspan="2">35'418'424</td></tr><tr><td>Net financial liabilities</td><td colspan="2">0</td><td colspan="2">0</td></tr><tr><td>Non-operating assets</td><td colspan="2">0</td><td colspan="2">0</td></tr><tr><td>Equity value (EUR)</td><td colspan="2">28'929'552</td><td colspan="2">35'418'424</td></tr><tr><td>Equity share Xlife Sciences</td><td colspan="2"></td><td>37.36%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td colspan="2">10'808'081</td><td colspan="2">13'232'323</td></tr><tr><td>Exchange rate EUR/CHF</td><td colspan="2"></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td colspan="2">10'700'000</td><td colspan="2">13'100'000</td></tr></table>					from		to		Company valuation (100%) (EUR)	28'929'552		35'418'424		Net financial liabilities	0		0		Non-operating assets	0		0		Equity value (EUR)	28'929'552		35'418'424		Equity share Xlife Sciences			37.36%		Equity value Xlife Sciences share (EUR)	10'808'081		13'232'323		Exchange rate EUR/CHF			0.99		Equity value Xlife Sciences share (CHF)	10'700'000		13'100'000	
	from		to																																															
Company valuation (100%) (EUR)	28'929'552		35'418'424																																															
Net financial liabilities	0		0																																															
Non-operating assets	0		0																																															
Equity value (EUR)	28'929'552		35'418'424																																															
Equity share Xlife Sciences			37.36%																																															
Equity value Xlife Sciences share (EUR)	10'808'081		13'232'323																																															
Exchange rate EUR/CHF			0.99																																															
Equity value Xlife Sciences share (CHF)	10'700'000		13'100'000																																															
Founded	Share	Exit scenario	Location	Website																																														
2010	37.36%	License	Vaduz, Liechtenstein	www.synimmune.de																																														

\* Values rounded



# xarma life sciences GmbH


## Fact Sheet


<div>Activity &amp; Business model</div> <div><ul style="list-style-type: none"><li>Development of first-in-class functional antibodies for G-coupled proteins for treatment of indications with unmet medical needs (currently one antibody)</li><li>Partner of Veraxa Biotech</li><li>License model</li></ul></div>		<div>Development phase</div> <div></div>		<div>Portfolio segment</div> <div><div>Platform</div><div>BioTech</div><div>MedTech</div><div>AI</div><div>BioTech</div></div>																																					
<div>Modeling</div> <div><ul style="list-style-type: none"><li>Category: Equity</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 4 years from 2040</li><li>Cum Success Rate: 10% from 2030</li><li>WACC / Rational: 20% / Early stage start-up company</li></ul></div>		<div>Valuation</div> <table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>7'869'214</td><td colspan="2">9'617'928</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>7'869'214</td><td colspan="2">9'617'928</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>46.21%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>3'636'364</td><td colspan="2">4'444'444</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>3'600'000</td><td colspan="2">4'400'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	7'869'214	9'617'928		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	7'869'214	9'617'928		Equity share Xlife Sciences		46.21%		Equity value Xlife Sciences share (EUR)	3'636'364	4'444'444		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	3'600'000	4'400'000	
	from	to																																							
Company valuation (100%) (EUR)	7'869'214	9'617'928																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	7'869'214	9'617'928																																							
Equity share Xlife Sciences		46.21%																																							
Equity value Xlife Sciences share (EUR)	3'636'364	4'444'444																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	3'600'000	4'400'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2020	46.21%	License	Mainz, Germany	www.xlifesciences.ch/projects																																					

\* Values rounded



# Axenoll Life Sciences AG

## Fact Sheet




Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>3D screen printing of biomaterials for applications in the medical and biotechnology sector</li><li>Established company</li><li>Manufacturer</li></ul>		 <div>Operating</div>		<div><div>Platform</div><div>BioTech</div><div>MedTech</div><div>AI</div></div> <div>MedTech</div>																																					
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Fair Value</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 70%</li><li>WACC / Rational: 15.24% / Established company, technology shows high leverage potentials</li></ul>		<table><thead><tr><th></th><th>from</th><th colspan="2">to</th></tr></thead><tbody><tr><td>Company valuation (100%) (EUR)</td><td>127'979'870</td><td colspan="2">156'901'875</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>127'979'870</td><td colspan="2">156'901'875</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>13.97%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>17'878'788</td><td colspan="2">21'919'192</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>17'700'000</td><td colspan="2">21'700'000</td></tr></tbody></table>					from	to		Company valuation (100%) (EUR)	127'979'870	156'901'875		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	127'979'870	156'901'875		Equity share Xlife Sciences		13.97%		Equity value Xlife Sciences share (EUR)	17'878'788	21'919'192		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	17'700'000	21'700'000	
	from	to																																							
Company valuation (100%) (EUR)	127'979'870	156'901'875																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	127'979'870	156'901'875																																							
Equity share Xlife Sciences		13.97%																																							
Equity value Xlife Sciences share (EUR)	17'878'788	21'919'192																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	17'700'000	21'700'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2014	13.97%	License / Sale	Zurich, Switzerland	www.axenoll.com																																					

\* Values rounded

Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>▪ Development of hollow bodies / tubes from biocellulose for surgical use, so far primarily in bile area</li><li>▪ Spin-off University Hospital Jena</li><li>▪ License model</li></ul>																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>▪ Category: Fully consolidated</li><li>▪ Method: rNPV</li><li>▪ Terminal Value: Phase Out 5 years</li><li>▪ Cum Success Rate: 42%</li><li>▪ WACC / Rational: 17.78% / Startup, first animal studies been successful</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>1'298'701</td><td colspan="2">1'587'302</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>1'298'701</td><td colspan="2">1'587'302</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>70.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>909'091</td><td colspan="2">1'111'111</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>900'000</td><td colspan="2">1'100'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	1'298'701	1'587'302		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	1'298'701	1'587'302		Equity share Xlife Sciences		70.00%		Equity value Xlife Sciences share (EUR)	909'091	1'111'111		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	900'000	1'100'000	
	from	to																																							
Company valuation (100%) (EUR)	1'298'701	1'587'302																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	1'298'701	1'587'302																																							
Equity share Xlife Sciences		70.00%																																							
Equity value Xlife Sciences share (EUR)	909'091	1'111'111																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	900'000	1'100'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2019	70.00%	License / Sale	Erfurt, Germany	www.clyxopdevices.com																																					



\* Values rounded



Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Development of screening tools for early detection of neurodegenerative diseases with focus on Parkinson’s and Alzheimer’s disease, tool Neuromex</li><li>Spin-off University Clinic Jena, European patent, FDA patent application filed</li><li>Manufacturer</li></ul>				<table><tr><td>Platform</td><td>BioTech</td><td>MedTech</td><td>AI</td></tr><tr><td colspan="4">MedTech</td></tr></table>		Platform	BioTech	MedTech	AI	MedTech																															
Platform	BioTech	MedTech	AI																																						
MedTech																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Fair Value</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 77%</li><li>WACC / Rational: 15.24% / technology fully developed, going to market as upcoming challenge</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>41’998’937</td><td colspan="2">51’568’315</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>41’998’937</td><td colspan="2">51’568’315</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>19.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>7’979’798</td><td colspan="2">9’797’980</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>7’900’000</td><td colspan="2">9’700’000</td></tr></table>					from	to		Company valuation (100%) (EUR)	41’998’937	51’568’315		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	41’998’937	51’568’315		Equity share Xlife Sciences		19.00%		Equity value Xlife Sciences share (EUR)	7’979’798	9’797’980		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	7’900’000	9’700’000	
	from	to																																							
Company valuation (100%) (EUR)	41’998’937	51’568’315																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	41’998’937	51’568’315																																							
Equity share Xlife Sciences		19.00%																																							
Equity value Xlife Sciences share (EUR)	7’979’798	9’797’980																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	7’900’000	9’700’000																																							
Founded	Share	Exit scenario	Location	Website																																					
2019	19.00%	License / Trade sale	Erfurt, Germany	www.sanivadiagnostics.com																																					

\* Values rounded





Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Development of new biomarkers for early detection of kidney disease</li><li>License model</li></ul>																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Fully consolidated</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 16%</li><li>WACC / Rational: 17.78% / Start-up company, first studies with positive results</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>3'131'313</td><td colspan="2">3'838'384</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>3'131'313</td><td colspan="2">3'838'384</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>100.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>3'131'313</td><td colspan="2">3'838'384</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>3'100'000</td><td colspan="2">3'800'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	3'131'313	3'838'384		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	3'131'313	3'838'384		Equity share Xlife Sciences		100.00%		Equity value Xlife Sciences share (EUR)	3'131'313	3'838'384		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	3'100'000	3'800'000	
	from	to																																							
Company valuation (100%) (EUR)	3'131'313	3'838'384																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	3'131'313	3'838'384																																							
Equity share Xlife Sciences		100.00%																																							
Equity value Xlife Sciences share (EUR)	3'131'313	3'838'384																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	3'100'000	3'800'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2019	100.00%	License / Sale	Erfurt, Germany	-																																					

\* Values rounded





Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Development of liver-specific PET tracers for use in nuclear medicine</li><li>Spin-off University Clinic Jena</li><li>License Model</li></ul>		 PoC		 MedTech																																					
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Fully consolidated</li><li>Method: rNPV</li><li>Terminal Value: Phase Out 5 years</li><li>Cum Success Rate: 36%</li><li>WACC / Rational: 17.78% / Start-up company, first studies show positive results</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>11'717'172</td><td colspan="2">14'343'434</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>11'717'172</td><td colspan="2">14'343'434</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>100.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>11'717'172</td><td colspan="2">14'343'434</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>11'600'000</td><td colspan="2">14'200'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	11'717'172	14'343'434		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	11'717'172	14'343'434		Equity share Xlife Sciences		100.00%		Equity value Xlife Sciences share (EUR)	11'717'172	14'343'434		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	11'600'000	14'200'000	
	from	to																																							
Company valuation (100%) (EUR)	11'717'172	14'343'434																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	11'717'172	14'343'434																																							
Equity share Xlife Sciences		100.00%																																							
Equity value Xlife Sciences share (EUR)	11'717'172	14'343'434																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	11'600'000	14'200'000																																							
Founded	Share	Exit scenario	Location		Website																																				
2019	100.00%	License / Sale	Erfurt, Germany		www.xlifesciences.ch/projects																																				

\* Values rounded

Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>Contactless and AI based capturing of diagnostic health data through optical parameters (photonics)</li><li>Manufacturer</li></ul>																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Fair Value</li><li>Method: rNPV</li><li>Terminal Value: Phase out 5 years</li><li>Cum Success Rate: 20%</li><li>WACC / Rational: 22.86% / Early stage start-up company</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>21'085'859</td><td colspan="2">25'757'576</td></tr><tr><td>Net financial liabilities</td><td>0</td><td></td><td>0</td></tr><tr><td>Non-operating assets</td><td>0</td><td></td><td>0</td></tr><tr><td>Equity value (EUR)</td><td>21'085'859</td><td colspan="2">25'757'576</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>80.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>16'868'687</td><td colspan="2">20'606'061</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>16'700'000</td><td colspan="2">20'400'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	21'085'859	25'757'576		Net financial liabilities	0		0	Non-operating assets	0		0	Equity value (EUR)	21'085'859	25'757'576		Equity share Xlife Sciences		80.00%		Equity value Xlife Sciences share (EUR)	16'868'687	20'606'061		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	16'700'000	20'400'000	
	from	to																																							
Company valuation (100%) (EUR)	21'085'859	25'757'576																																							
Net financial liabilities	0		0																																						
Non-operating assets	0		0																																						
Equity value (EUR)	21'085'859	25'757'576																																							
Equity share Xlife Sciences		80.00%																																							
Equity value Xlife Sciences share (EUR)	16'868'687	20'606'061																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	16'700'000	20'400'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2021	80.00%	License / Sale	Jena, Germany	www.xsightoptics.com																																					

\* Values rounded



Activity & Business model		Development phase		Portfolio segment																																					
<ul style="list-style-type: none"><li>AI-supported software for improvement of diagnostics in radiology</li><li>Manufacturer &amp; service provider (Software as a Services, SaaS)</li></ul>																																									
Modeling		Valuation																																							
<ul style="list-style-type: none"><li>Category: Equity</li><li>Method: rNPV</li><li>Terminal Value: Perpetual Growth Rate 5%</li><li>Cum Success Rate: 38%</li><li>WACC / Rational: 15.24% / Established company with proven products &amp; technology</li></ul>		<table><tr><th></th><th>from</th><th colspan="2">to</th></tr><tr><td>Company valuation (100%) (EUR)</td><td>92'352'092</td><td colspan="2">113'131'313</td></tr><tr><td>Net financial liabilities</td><td>0</td><td colspan="2">0</td></tr><tr><td>Non-operating assets</td><td>0</td><td colspan="2">0</td></tr><tr><td>Equity value (EUR)</td><td>92'352'092</td><td colspan="2">113'131'313</td></tr><tr><td>Equity share Xlife Sciences</td><td></td><td>35.00%</td><td></td></tr><tr><td>Equity value Xlife Sciences share (EUR)</td><td>32'323'232</td><td colspan="2">39'595'960</td></tr><tr><td>Exchange rate EUR/CHF</td><td></td><td>0.99</td><td></td></tr><tr><td>Equity value Xlife Sciences share (CHF)</td><td>32'000'000</td><td colspan="2">39'200'000</td></tr></table>					from	to		Company valuation (100%) (EUR)	92'352'092	113'131'313		Net financial liabilities	0	0		Non-operating assets	0	0		Equity value (EUR)	92'352'092	113'131'313		Equity share Xlife Sciences		35.00%		Equity value Xlife Sciences share (EUR)	32'323'232	39'595'960		Exchange rate EUR/CHF		0.99		Equity value Xlife Sciences share (CHF)	32'000'000	39'200'000	
	from	to																																							
Company valuation (100%) (EUR)	92'352'092	113'131'313																																							
Net financial liabilities	0	0																																							
Non-operating assets	0	0																																							
Equity value (EUR)	92'352'092	113'131'313																																							
Equity share Xlife Sciences		35.00%																																							
Equity value Xlife Sciences share (EUR)	32'323'232	39'595'960																																							
Exchange rate EUR/CHF		0.99																																							
Equity value Xlife Sciences share (CHF)	32'000'000	39'200'000																																							
Founded	Share	Exit scenario	Location	Website																																					
2017	35.00%	License / Sale	Hamburg, Germany	www.fuse-ai.de																																					

\* Values rounded



# Xlife Sciences AG Valuation Report 2022

## Table of content

### Executive Summary

Page 4

### Portfolio analysis

Page 7

### Valuation of project companies in detail

Page 15

### Appendix

Page 34

# Appendix A

## Valuation approach & key assumptions (1/2)

The current value of Xlife Sciences AG's shares in project companies were determined on the basis of the provided business plans using professional valuation methods:

The risk-adjusted net present value (rNPV) method was used for the majority of all investments. Exceptionally, the classic net present value method (NPV) was used for companies already operating on the market with fully developed products.

The risk-adjusted net present value (rNPV) is a method for valuing risky cash flows with special consideration of the underlying development risks. The rNPV method is generally used to value individual products that are usually in development, i.e. specifically in the biotech and pharmaceutical industries.

The probability of occurrence (success rates) can be estimated on the basis of comparable projects. In biotechnology, for example, one calculates the average probability that a product in a certain field will reach the next development phase (e.g. clinical phases I, II or III).

The rNPV method modifies the standard NPV calculation of discounted cash flows (DCF) analysis by multiplying each cash flow by the estimated probability of occurrence (expected value).

Compared to the classic NPV method, market risks and development risks are accounted for separately and reported by means of the applied cost of capital (weighted cost of capital, WACC) or accumulated success probabilities over the various development stages (cumulated success rates). This leads to comparatively lower cost of capital rates, which are however supplemented with an additional risk consideration, namely the development risks. Under the NPV method, all risks are accounted for cumulatively by the applied cost of capital rate.

The investments were valued as of the reporting date of December 31<sup>st</sup> 2022. The relevant periods under consideration vary depending on the project company-specific circumstances, but basically fall into two categories:

- A) The company has products still in development with / without initial patents and a medium to long-term business plan, which in particular includes a patent protection period of 20 years and a subsequent "meltdown phase" of four to five years, optionally with or without a certain lead time. In detail, the duration until market entry and the duration until reaching the targeted peak market share have to be differentiated.
- B) The company is already active on the market with developed products or offers non-patentable products or, in particular, services. In this case, there is no long-term protection period, and the planning periods are correspondingly shorter (for example, five years) with a subsequent residual value.

# Appendix A

## Valuation approach & key assumptions (2/2)

Residual values: The following values were considered as residual values remaining after the relevant observation period: A) The meltdown phase of four to five years with a successive decline in sales to a zero value or B) in a few cases a more standard terminal value, i.e. a perpetual residual cash flow.

Currency: The project companies of Xlife Sciences AG are mostly domiciled in Germany and operate in EUR, the values of the company shares of Xlife Sciences AG are shown in CHF, the exchange rate used is EUR/CHF 0.99.

As a cost of capital to capture the fundamental systemic market risks, a base WACC of 12.7% was derived from empirical comparative data on the application of NPV and rNPV within the biotech industry - corrected for the development of risk free rates within the relevant period. As a cross-check, these WACC figures were put into context with a peer group of listed companies.

Additional risk components such as e.g. the degree of development of the company (start-up) were captured by hurdle rates; 15.24% (WACC +20%), 17.78% (WACC + 40%), 20.32% (WACC + 60%), 22.86% (WACC + 80%) and 25.40% (WACC + 100%).

In applying the rNPV model, specific success rates (cumulative success rate) were used in each case based on the available empirical data of comparable development projects. In the case of upfront payments and total deal sizes to be taken into account, empirical comparative data, in particular for the years 2017-2020, were also used and compared with the respective estimated market potentials.

The business plans are generally based on a license deals setups, i.e. the project companies operate primarily as lean finance platforms for the numerous contractual agreements and license deals. Only in exceptional cases are the business plans based on the assumption that the respective products will also be manufactured (and possibly distributed, etc.) by the project companies themselves. These two basic orientations are reflected in the respective revenue and cost structures.

To check the plausibility of the underlying cost structures, the assumptions were compared with a peer group of the top 36 pharmaceutical companies of the S&P 500 where possible and reasonable. Within the framework of statistical tolerance values (confidence intervals), the assumptions were compared for noticeable inconsistencies and deviations.

As a matter of principle, the project companies have neither significant financial liabilities nor non-operating assets at the time of valuation; the company values therefore correspond to the equity values. The overall valuation is the sum of the individual valuations. Market & development risks were taken into account for the respective individual investments and consistent valuation ranges were shown in detail.

# Appendix B

## Valuation process incl. details on interviews & on site visits

### Cylad team

Dr. oec. HSG Hans Geiser  
Partner Zurich Office  
hans.geiser@cylad.com

Dominik Marti, Dipl. Ing. ETH  
Partner Zurich Office  
dominik.marti@cylad.com

Cylad Experts AG  
Center Staldenbach 5  
CH-8808 Pfäffikon SZ

### Valuation process incl. interviews & on site visits

- 1 Review of data provided by Xlife Sciences / project companies
- 2 Interviews & discussions with management members
- 3 On site visits at facilities of largest portfolio-companies
- 4 Setting up a valuation model, performing valuation analysis
- 5 Create Valuation Report 2022

### Cylad has performed interviews with all evaluated Xlife Sciences project-companies

The Cylad team has personally spoken to management representatives of all Xlife Sciences project-companies which have been evaluated in 2022. This includes the following project-companies of the Xlife Sciences portfolio: alytas therapeutics GmbH, Axenoll Life Sciences AG, clyxop devices GmbH, FUSE-AI GmbH, inflamed pharma GmbH, Inventum Genetics GmbH, Ix Therapeutics GmbH, Lysatpharma GmbH, palleos healthcare GmbH, QUADIRA BIOSCIENCES AG, saniva diagnostics GmbH, Synimmune Biotech AG, Veraxa Biotech AG, xarma life sciences GmbH, x-kidney diagnostics GmbH, x-nuclear diagnostics GmbH, Xsight Optics GmbH.

### Visits of largest project-companies have taken place in 3&4Q2022

The cylad team has personally visited the facilities of the major project companies and met with representatives of the respective managements:

FUSE-AI GmbH, Kantonsspital Aarau, Switzerland, October 26th 2022, Dr. F. Brun, M. Steffen (Demo at customer location)

Inventum Genetics GmbH, Uniklinikum Marburg, Germany, Nov 7th 2022, Prof. Dr. J. Schuhmacher, Dr. A. Zink

alytas therapeutics GmbH, Uniklinikum Marburg, Germany, Nov 7th 2022, Dr. A. Zink

Axenoll Life Sciences AG, Jena, Germany, Nov 8th 2022, S. Madej

inflamed pharma GmbH, Jena, Germany, Nov 8th 2022, Dr. B. Engert, Dr. F. Plöger

Lysatpharma GmbH, Eisenberg, Germany, Nov 9th 2022, Dr. K. de Miroschedij, Dr. F. Plöger

Veraxa Biotech AG, Nov 10th 2022, Heidelberg, Germany, Dr. C. Antz, T. Bürgermeister, Dr. L. Hufnagel

### No interviews / contacts with companies that have not been evaluated by Cylad (yet)

Cylad did not have contact with: Baliopharm AG, Laxxon Medical Corp., novaxomx GmbH, Novum Technologie GmbH, panmabs GmbH, VITRUVIA MEDICAL AG, XRNA Biotech GmbH, x-diagnostics GmbH, xprot GmbH.

# Appendix C

## WACC

### WACC Calculation

Risk free rate	2.15%	10y government bond yield of Germany in local currency
Market risk premium	7.60%	Market risk premium for German Health Care & Pharma markets
Adjusted unlevered beta	1.108	Derived from peer group analysis median value with adjustments
Adjusted levered beta	1.132	Derived from peer group analysis median value with adjustments
Size premium	2.15%	Size premium with special consideration of current portfolio mix
<b>Cost of equity</b>	<b>12.90%</b>	
Risk free rate	2.15%	10y government bond yield of Germany in local currency
Credit spread	0.60%	Credit spread comparable corporate yield curve (corporates, BBB, 10y)
<b>Cost of debt</b>	<b>2.75%</b>	
Equity ratio	97.89%	Capital structure derived from peer group median value
Debt ratio	2.11%	Capital structure derived from peer group median value
Corporate tax rate	30.00%	Total relevant tax burden in Germany (management assessments)
<b>WACC rounded</b>	<b>12.7%</b>	

### Remarks & Considerations

- All data as for End of December 2022
- Cylad feels comfortable to rely on German 10 year government bond yield with regard to the applicable risk free rate (operations of Xlife Sciences project companies basically all on German soil, focus on German market esp. in start up phase, balancing strong and partially diverging dynamics in risk free rate developments, e.g. Germany vs remaining European Union, USA).
- Market risk premium at the upper end of a 6 to 8% range due to the emphasis on early stage developments.
- Applicable size premium 2.15% out of a 1 to 3.5% because of considerable size of portfolio heavyweights alytas therapeutics GmbH & Veraxa Biotech AG.



WE HELP STRATEGIC AND OPERATIONAL LEADERS OF INDUSTRIAL COMPANIES  
TO DEVELOP BUSINESS, DRIVE SUSTAINABLE PERFORMANCE, & INCREASE  
AGILITY.

Projects in Europe, North America, Africa & Asia Pacific

[www.cylad-consulting.com](http://www.cylad-consulting.com) ▪ [www.cylad-experts.com](http://www.cylad-experts.com)